Creates a single source for large-scale
population studies, biobank characterization, and multi-omic
biomarker analysis to support drug and diagnostic
development
HUNTSVILLE, Ala., Dec. 14,
2022 /CNW/ -- Discovery Life
Sciences™ (Discovery) today announced the launch of its new
Proteomic Services Division and is now accepting samples from
pharmaceutical and biotech companies, government, and non-profit
and academic research centers. This innovative offering includes
both exploratory and targeted proteomics using the Seer
Proteograph™ Product Suite, SCIEX LC-MS/MS systems,
Olink® Proximity Extension Assay (PEA), and Luminex
xMAP® platforms.
Discovery's proteomic service laboratories are now integrated
with its market-leading short- and long-read genomic service
laboratories and expansive global commercial biorepository of
hyper-annotated® biospecimens.
"We are very excited to open our doors to researchers and
scientists worldwide and provide them access to Discovery's
highly-scaled, multi-omic services to advance their biomarker
discovery, clinical development, and large-scale research
programs," said Michael Pisano,
Discovery's executive vice president of Proteomics. "Our proteomic
experts carefully designed, built, and optimized a comprehensive,
platform-agnostic suite of leading-edge proteomic and
proteo-genomic technologies to support all biomarker strategies,
large-scale population studies, and biobank characterization
projects."
As a part of its biomarker services expansion strategy,
Discovery signed a multi-year agreement in January with Seer,
Inc. (NASDAQ: SEER), a life science company commercializing a
disruptive new platform for proteomics, and SCIEX, a global leader
in life science analytical technologies, to form a
first-of-its-kind Proteogenomics Consortium (PGC) for large-scale
plasma proteomic studies. The PGC combines the proprietary
technologies and expertise of all three companies to offer
unbiased, high-resolution proteogenomic services to help uncover
novel biomarkers that can be mapped back to underlying genetic
variations.
"The Proteogenomics Consortium strategically unites these highly
advanced plasma proteomic technologies with our world-leading
expertise in short- and long-read genomics to add deep, unbiased
proteomics data more easily to discovery, translational, and
clinical studies, as well as large-scale population research
programs," said Glenn Bilawsky, CEO
of Discovery. "In addition, the PGC also enables the creation
of new diagnostic tools for cancer, neurodegenerative,
inflammatory, infectious diseases, and other therapeutic
areas."
Then, in September, Discovery announced it was the largest
certified commercial service provider for the Olink® PEA
platform in the Americas. Olink's PEA is a unique immuno-PCR
technology that solves the dynamic range issue that has hindered
plasma proteomics for decades, allowing for the detection and
quantitation of low abundant proteins in plasma at
scale. Discovery will also implement complementary multiplex
immunoassay platforms, including xMAP® technology from
Luminex, enabling customizable protein and nucleic acid-based
multiplex assays.
Discovery offers a wide range of services, including genomics,
proteomics, pathology, and cell biology. Accompanying its extensive
service portfolio, Discovery has the world's largest commercial
biorepository, offering partners a single chain of custody to
accelerate clinical research and development. Discovery's
integrated, multi-omic workflow enables clients to gain deeper
insights while conserving precious samples.
About Discovery Life
Sciences
Discovery Life Sciences is the company of Biospecimen,
Biomarker, and Proteogenomic Specialists, combining the world's
largest commercial biospecimen inventory and procurement network
with preeminent multi-omic biomarker service laboratories,
including genomic, tissue biomarker, proteomic, and cell-based
services to accelerate new therapies supported by biomarker and
companion diagnostic programs for cancer, infectious disease, and
other rare and complex conditions.
Through AllCells®, our cell and gene therapy division, we
maintain the largest recallable donor pool to supply Research Use
Only (RUO) and clinical-grade fresh and cryopreserved human
cellular materials to support cell and gene therapy programs in any
phase of development and at any scale.
Driven by leading scientific expertise and innovative use of
current technologies, the Discovery team engages with customers to
rapidly overcome obstacles and obtain results to make critical
research and development decisions at market-leading speed. We are
Science at your Service™! For more information, visit
dls.com.
About Olink
Olink Holding AB (publ) (Nasdaq: OLK) is a company
dedicated to accelerating proteomics together with the scientific
community across multiple disease areas to enable new discoveries
and improve the lives of patients. Olink provides a platform of
products and services which are deployed across major
pharmaceutical companies and leading clinical and academic
institutions to deepen the understanding of real-time human biology
and drive 21st-century healthcare through actionable and
impactful science. The company was founded in 2016 and is
well-established across Europe,
North America, and Asia. Olink is headquartered in Uppsala,
Sweden.
About SCIEX
SCIEX delivers solutions for the precision detection and
quantification of molecules, empowering our customers to protect
and advance the wellness and safety of all. We have been at the
forefront of the field of mass spectrometry for 50 years. From the
launch of the first ever commercially successful triple quadrupole
in 1981, we have developed groundbreaking technologies and
solutions that influence life-changing research and
outcomes.
Today, we continue to pioneer robust solutions in mass
spectrometry and capillary electrophoresis. Our customers are able
to quickly respond to environmental hazards, better understand
biomarkers relevant to disease, improve patient care in the clinic,
bring relevant drugs to market faster and keep food healthier and
safer.
That's why thousands of life science experts around the world
choose SCIEX to get the answers they can trust to better inform
critical decisions that positively impact lives.
For more information, please visit
www.sciex.com.
About Seer
Seer™ is a life sciences company developing transformative
products that open a new gateway to the proteome. Seer's
Proteograph™ Product Suite is an integrated solution that includes
proprietary engineered nanoparticles, consumables, automation
instrumentation, and software to perform unbiased, deep, and rapid
proteomic analysis at scale in a matter of hours. Seer designed the
Proteograph workflow to be efficient and easy to use, leveraging
widely adopted laboratory instrumentation to provide a
decentralized solution that can be incorporated by nearly any lab.
Seer's Proteograph Product Suite is for research use only and is
not intended for diagnostic procedures. For more information,
please visit www.seer.bio.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/discovery-life-sciences-launches-world-class-proteomic-services-division-supported-by-leading-technology-partners-301702522.html
SOURCE Discovery Life Sciences